Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD128 in Obstructive Sleep Apnea
NCT04394143Phase 3Completed
- Start
- Oct 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of reboxetine + oxybutynin in obstructive sleep apnea (OSA). Started Oct 2020; status: completed.
02
Drugs
reboxetine + oxybutynin
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT04394143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04394143.